ZyVersa Therapeutics has filed an S-3 registration statement for the potential resale of up to 1,637,000 shares of common stock by warrant holders. The shares are issuable upon exercise of Series A-2 warrants issued in a November 2024 private placement at $2.06 per share.The company will not receive proceeds from the resale of shares by selling stockholders. However, ZyVersa could receive up to $3.37 million in gross proceeds if all warrants are exercised for cash. Any proceeds would be used for working capital and general corporate purposes.ZyVersa is a clinical-stage biopharmaceutical company developing treatments for renal and inflammatory diseases. Its lead candidate VAR 200 is in Phase 2a trials for diabetic kidney disease and focal segmental glomerulosclerosis. The company's preclinical asset IC 100 targets inflammatory conditions.

ZyVersa Therapeutics has filed an S-3 registration statement for the potential resale of up to 1,637,000 shares of common stock by warrant holders. The shares are issuable upon exercise of Series A-2 warrants issued in a November 2024 private placement at $2.06 per share.The company will not receive proceeds from the resale of shares by selling stockholders. However, ZyVersa could receive up to $3.37 million in gross proceeds if all warrants are exercised for cash. Any proceeds would be used for working capital and general corporate purposes.ZyVersa is a clinical-stage biopharmaceutical company developing treatments for renal and inflammatory diseases. Its lead candidate VAR 200 is in Phase 2a trials for diabetic kidney disease and focal segmental glomerulosclerosis. The company's preclinical asset IC 100 targets inflammatory conditions.